The budget was never cut. It was appropriated in full, defended in committee, and then quietly rerouted through an accounting rule that funds fewer laboratories with exactly the same money.
The federal fiscal year ends on September 30, which gives the National Institutes of Health five days to obligate whatever remains of a $47 billion appropriation before the unspent portion goes back to the Treasury. This is the second consecutive year the agency has arrived at the deadline sprinting, and the second consecutive year that sprint will produce thousands fewer new grants than it did before 2025.
Most coverage of this has framed it as a delay story, which is understandable, because the delays are real and well documented. Grant renewals ran 90 or more days late at four to six times the historical rate. The agency spent much of the year 42 to 44 days behind its own normal pace. Halfway through the fiscal year, at the end of March, NIH had obligated $5.8 billion of its external research budget, about 15 percent, against nearly $9 billion by the same date in the last full year of the previous administration. NPR laid the trajectory out in six charts this week.
But a delay is a thing you can catch up on, and the catching up is the part that does the damage. The durable change here is not the calendar. It is a budget-execution rule that almost nobody outside university finance offices has bothered to explain, and it is the reason a level-funded agency is shrinking.
The Rule That Turns Level Funding Into a Cut
Traditionally, NIH committed a multiyear research grant one year at a time: a five-year project drew from five consecutive appropriations. Under multiyear lump-sum funding, sometimes called forward funding, the agency obligates the entire project period out of a single year’s money at the moment of the initial award. The arithmetic is not subtle. If every grant now consumes all of its future years upfront, the same appropriation supports a fraction of the laboratories it used to.
This is not a theory about what might happen. Last year the practice meant NIH funded roughly 2,800 fewer new grants than its own average across fiscal 2021 through 2024. NIH’s internal guidance predicted the outcome before it occurred, saying a requirement to push half of its funding through multiyear awards was expected to lead to fewer awards and support for fewer researchers overall. The risks to research continuity were flagged in May, and by March the AAMC was already warning that a late-year rush would force exactly this reliance on lump-sum awards. It did.
The success rates tell you where it landed. At the National Cancer Institute, the odds of an applicant winning a grant fell from roughly one in ten to one in twenty-five. Across NIH, 17 percent of research-grant applicants received an award in fiscal 2025, the lowest rate in three decades.
Congress noticed. Lawmakers wrote a cap into an appropriations act barring NIH from obligating more toward multiyear grants this year than it did last year, which is a strange and telling thing to have to legislate. Congress had already rejected the administration’s proposed 41 percent cut, about $19.6 billion, and funded the agency at prior-year levels. Having appropriated the money, it then had to pass a second provision instructing the executive branch not to spend it in a way that defeats the purpose of appropriating it.
That is the story, and it deserves to be said without hedging. An administration that lost the budget fight in Congress achieved a meaningful part of the same result through execution mechanics: slow obligation, a lump-sum rule that thins the applicant pool, grants-management offices cut to a fraction of their staff, with one institute going from thirteen specialists to three. Research on racial and ethnic minority health fell by more than $1 billion, a 29 percent drop, while artificial intelligence work rose by $468 million. Nobody voted for that reallocation. It was produced by who processes which paperwork, and how fast.
The catch-up sprint now underway will let officials report that the money went out the door. It will be true, and it will be the least informative true thing available. The dollars will clear. The question worth asking on October 1 is how many laboratories they landed in, and that number has been falling for two years for reasons the top line was never going to show.